VIB presents its annual results at BIO2004 in San Francisco

June 03, 2004

San Francisco, BIO2004; The North American biotech convention 'BIO' has blossomed into the place to be. Every year, the international biotech community gathers together at this mega-happening, which this year boasts 20,000 participants. VIB (the Flanders Interuniversity Institute for Biotechnology) is coordinating the Belgian delegation to 'BIO 2004' in San Francisco, where it will present its newly published annual results. These latest results from 2003 - with the large number of major research breakthroughs, 30 patent applications, and almost 50 agreements with industry - clearly position VIB among the top in the world.

In 2003, VIB scientists achieved 180 significant breakthroughs in a variety of domains such as cancer, Alzheimer's disease, inflammatory diseases, human genetics, and plant growth. This figure surpasses that of the previous year, which was already three times as many as at the start of the institute in 1995. This result vaults Flanders' biotechnological research to the top internationally. Also in 2003, VIB expanded its research groups with 3 new ones active in emerging fields in the life sciences. In fact, this is an instance of reverse brain drain, because, after an international search, 3 Belgians proved to be the best candidates and they were eager to return to Flanders after successful careers abroad.

VIB's innovative knowledge is a continuous source of new technologies and inventions that can form the basis for new social and industrial applications, including medical diagnostics and medicines. To bring these applications into being, VIB protects its findings via patents: in 2003, 30 discoveries were sufficiently new and inventive to warrant patent applications. At the same time, VIB entered into nearly 50 collaborative agreements with business and industry. In addition, VIB was the catalyst for the creation of a new network - called 'FlandersBio' - that unites the Flemish biotech industry.
-end-
Along with VIB, 9 Flemish biotech companies will present their breakthroughs and expertise at BIO2004 in San Francisco. They are part of the Belgian delegation that includes over 70 participants. The 9 Flemish companies are: Algonomics; CropDesign; De Clercq, Brants & Partners; Innogenetics; Msource Medical Developments; Perseus; Tigenix; Thromb-X; and Xcellentis. (The attachment provides a brief description of these participating companies.)

On the VIB website (http://www.vib.be/VIB/EN/Downloads/Annual+report/) you can find our new Annual Report. This will provide you with an overview of our research and other activities in 2003.

VIB (the Flanders Institute for Biotechnology)

Related Biotechnology Articles from Brightsurf:

Cyanobacteria as "green" catalysts in biotechnology
Researchers from TU Graz and Ruhr University Bochum show in the journal ACS Catalysis how the catalytic activity of cyanobacteria, also known as blue-green algae, can be significantly increased.

Biotechnology to the rescue of Brussels sprouts
An international team has identified the genes that make these plants resistant to the pathogen that attacks crops belonging to the cabbage family all over the world.

UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.

Faster genome evolution methods to transform yeast for industrial biotechnology
A research team led by Prof. DAI Junbiao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, in collaboration with Prof.

New innovations in cell-free biotechnology
Professor Michael Jewett's new platform to conduct cell-free protein synthesis could lead to improved quality of manufactured protein therapeutics and biomaterials.

Silk 'micrococoons' could be used in biotechnology and medicine
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.

Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.

China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.

Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.

Read More: Biotechnology News and Biotechnology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.